Perhaps Rash SHOULD be a Critical Factor in Clarifying Who Benefits from an EGFR Inhibitor: The TOPICAL Study
Nov 25, 2012•7 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. H. Jack West reviews the TOPICAL study of Tarceva vs. placebo for marginal and poor PS patients with advanced NSCLC, which showed a clearly superior outcome with Tarceva in patients who developed a rash vs. those who don't.
For the best experience, listen in Metacast app for iOS or Android